PROCEPT BioRobotics stock: MarketBeat cites a USD 25.50 target for PROCEPT BioRobotics stock

Published on 10/28/2026 at 07:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue rose 19.30 percent to USD 94.50 million. November 4, 2026 is the next results date for PROCEPT BioRobotics stock.

Analyst target and reporting dates

MarketBeat reported a USD 25.50 average target from 16 analysts on October 15, 2026.
Second-quarter revenue reached USD 94.50 million, up 19.30 percent year over year.
PROCEPT BioRobotics had a USD 1.1 billion market capitalization as of October 28, 2026.

PRCT, US74276L1052, Illustration mit AI erstellt.

PROCEPT BioRobotics (ISIN US74276L1052) drew a USD 25.50 average price target from 16 analysts in a Hold consensus reported by MarketBeat on October 15, 2026. The next quarterly report is scheduled for November 4, 2026.

Revenue grows while losses persist

PROCEPT BioRobotics generated USD 94.50 million in revenue during the second quarter of 2026, a 19.30 percent increase from the same period a year earlier. The company reported a diluted loss of USD 0.47 per share for that quarter, compared with a USD 0.35 loss a year earlier, according to MarketBeat.

Three dates shape the setup

The recent chronology has three measurable markers. On August 4, 2026, second-quarter revenue reached USD 94.50 million, while the diluted loss was USD 0.47 per share. On October 12, 2026, PROCEPT BioRobotics announced that third-quarter results would follow on November 4, 2026, after the market close, according to PROCEPT BioRobotics. On October 15, 2026, MarketBeat cited 16 analyst ratings and a USD 25.50 average target.

What does the target imply?

The analyst target sits above the latest reported Nasdaq quote, but the comparison is in different currencies from the German investor perspective. PRCT was last at USD 19.80 on Nasdaq on October 27, 2026 at 4:00 p.m. ET. The company had a USD 1.1 billion market capitalization as of October 28, 2026, while its 52-week range stood at USD 16.66 to USD 38.11.

Dates investors can verify

The next reporting date is November 4, 2026, with management scheduled to host a conference call at 4:30 p.m. ET, according to GlobeNewswire. Barron's lists March 2, 2027 as the scheduled date for full-year 2026 earnings.

Nasdaq valuation remains central

PROCEPT BioRobotics develops surgical robotics and image-guided systems for urologic procedures. The company manufactures the AQUABEAM and HYDROS Robotic Systems, with Aquablation therapy focused initially on benign prostatic hyperplasia, according to its investor-relations materials. The combination of 19.30 percent quarterly revenue growth and a USD 26.9 million quarterly net loss leaves the November report as the next concrete test of operating leverage.